Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	23840
Country	United States

Received	2015-12-20 15:11
Peer-Review Started	2015-12-22 10:27
To Make the First Decision	2016-02-22 10:22
Return for Revision	2016-02-22 14:29
Revised	2016-02-23 18:10
Second Decision	2016-03-07 15:26
Accepted by Journal Editor-in-Chief	2016-03-07 23:48
Accepted by Executive Editor-in-Chief	2016-03-16 16:05
Articles in Press	2016-03-16 16:05
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-04-14 22:08
Publish the Manuscript Online	2016-04-20 23:11

ISSN	2150-5349 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Systematic Reviews
Article Title	Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration
Manuscript Source	Invited Manuscript
All Author List	Klaus Bielefeldt
Funding Agency and Grant Number
Corresponding Author	Klaus Bielefeldt, MD, PhD, Division of Gastroenterology, University of Pittsburgh Medical Center, 200 Lothrop St. Pittsburgh, PA 15217, United States. bielefeldtk@upmc.edu
Key Words	Sacral nerve stimulation; Implanted medical devices; Treatment complications; Defecation disorders; Device registry
Core Tip	Sacral neuromodulation can improve fecal incontinence refractory to other treatments. However, adverse events are very common and often require additional operations. Many of the reported patient concerns surface early after stimulator implantation, respond to changes in stimulation parameters and may thus be considered a part of the routine maintenance of this treatment modality. Nonetheless, rates of surgical re-interventions are high and increase over time. Physicians counseling patients about this treatment for fecal incontinence should emphasize the likely need for such secondary surgeries and consider emerging non-invasive treatment options. In addition, prospective studies should compare less invasive paradigms, such as transcutaneous stimulation, with permanently implanted devices to more clearly define their differential impact.
Publish Date	2016-04-20 23:11
Citation	Bielefeldt K. Adverse events of sacral neuromodulation for fecal incontinence reported to the federal drug administration. World J Gastrointest Pharmacol Ther 2016; 7(2): 294-305
URL	http://www.wjgnet.com/2150-5349/full/v7/i2/294.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v7.i2.294

Full Article (PDF)	WJGPT-7-294.pdf
Full Article (Word)	WJGPT-7-294.doc
Manuscript File	23840-Review.docx
Answering Reviewers	23840-Answering reviewers.pdf
Audio Core Tip	23840-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	23840-Conflict-of-interest statement.pdf
Copyright License Agreement	23840-Copyright assignment.pdf
Peer-review Report	23840-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	23840-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	23840-Scientific misconduct check.pdf
Scientific Editor Work List	23840-Scientific editor work list.pdf